NEW YORK (GenomeWeb) – Orig3N, a biotechnology firm developing a disease-modeling platform targeting rare genetically inherited diseases, today announced it raised $3.1 million in a private round of financing. 

The proceeds will go toward expanding Boston-based Orig3N's Life Capsule, a bio-repository for people to contribute their cells via a blood sample. The cells are reprogrammed into induced pluripotent stem cells, which can be used for disease modeling outside the body for medical research, as well as for individualized therapy. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.